葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓创新药及产业链仍是布局主要方向

智通财经07-21

智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。持仓方面，该基金前十大重仓股依次为：凯莱英(002821.SZ)、百利天恒(688506.SH)、恒瑞医药(600276.SH)、药明康德(603259.SH)、海思科(002653.SZ)、康龙化成(300759.SZ)、科伦药业(002422.SZ)、泰格医药(300347....

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2653733442?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-21 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653733442","market":"hk","top_or_hot":-1,"title":"葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。持仓方面，该基金前十大重仓股依次为：凯莱英(002821.SZ)、百利天恒(688506.SH)、恒瑞医药(600276.SH)、药明康德(603259.SH)、海思科(002653.SZ)、康龙化成(300759.SZ)、科伦药业(002422.SZ)、泰格医药(300347....</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1470368.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-21 17:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1470368.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。持仓方面，该基金前十大重仓股依次为：凯莱英(002821.SZ)、百利天恒(688506.SH)、恒瑞医药(600276.SH)、药明康德(603259.SH)、海思科(002653.SZ)、康龙化成(300759.SZ)、科伦药业(002422.SZ)、泰格医药(300347....</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1470368.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1470368.html","article_id":"2653733442","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653733442","pubTimestamp":1784625396,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。此外，君实生物新进持仓前十，信立泰跌出十大重仓。葛兰在季报中指出，2026年第二季度，市场风格分化显著，医药生物板块经历大幅震荡，整体走势弱于大盘。葛兰表示，第三季度创新药及产业链仍是布局的主要方向。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159760":"医疗健康","159992":"创新药","688180":"君实生物-U","BK0239":"医药制造","BK1583":"高瓴概念","IXJ":"全球医疗业ETF-iShares","BK4585":"ETF&股票定投概念","IBBQ":"Invesco Nasdaq Biotechnology ETF","06978":"永泰生物-B","BK4550":"红杉资本持仓","LABU":"三倍做多标普生物-Direxion","LNGR":"Global X Longevity Thematic ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","VHT":"Vanguard Health Care ETF","BK1161":"生物科技","BK4588":"碎股","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","01877":"君实生物","BK1515":"抗疫概念","BK1574":"生物医药B类股"},"translate_title":"Gulen's China-Europe Healthcare Mixed Second Quarterly Report: Junshi Biotech (688180.SH) has entered the top ten new heavy-duty innovative drugs and industrial chains, which are still the main direction of layout","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159760":1.5,"159992":1.5,"688180":1.5,"XLV":1.5,"IXJ":1.5,"MEDX":1.5,"IBBQ":1.5,"06978":1.5,"LNGR":1.5,"01877":1.5,"XBI":0.6,"VHT":1.5,"LABU":0.6},"content_text":"智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。持仓方面，该基金前十大重仓股依次为：凯莱英(002821.SZ)、百利天恒(688506.SH)、恒瑞医药(600276.SH)、药明康德(603259.SH)、海思科(002653.SZ)、康龙化成(300759.SZ)、科伦药业(002422.SZ)、泰格医药(300347.SZ)、艾力斯(688578.SH)、君实生物(688180.SH)。展望第三季度，葛兰认为创新仍是行业的核心增长动力，内需板块尚处调整阶段。调仓换股方面，与第一季度相比，中欧医疗健康加仓百利天恒、科伦药业、海思科、恒瑞医药、康龙化成，而泰格医药、艾力斯获减仓。此外，君实生物新进持仓前十，信立泰跌出十大重仓。业绩表现上，报告期内，基金A类份额净值增长率为4.09%，同期业绩比较基准收益率为-4.48%；基金C类份额净值增长率为3.88%，同期业绩比较基准收益率为-4.48%。葛兰在季报中指出，2026年第二季度，市场风格分化显著，医药生物板块经历大幅震荡，整体走势弱于大盘。申万医药生物指数季度内下跌9.45%，落后同期上涨11.90%的沪深300指数，在申万一级行业中排名靠后。细分板块分化剧烈，医疗研发外包以16.31%的涨幅成为板块内唯一取得正收益的方向，其余子行业全部下跌。估值层面，经过前期调整，医药板块整体估值风险已得到较充分释放，相对其他行业的性价比开始显现。葛兰表示，第三季度创新药及产业链仍是布局的主要方向。WCLC、ESMO等学术会议是国产创新药数据读出的重要窗口。BD出海品种的海外临床推进，也将迎来密集收获期，PD1/VEGF 双抗、CLDN18.2 ADC、TROP2 ADC等多个产品有望在下半年取得海外III期临床结果，国产新药正走在海外商业化集体兑现的前夜。第三季度医药行业投资将围绕“创新药及产业链”核心主线，兼顾“国产替代”的长期产业趋势与“消费医疗”的复苏预期。整体而言，中国创新药已迈入全线发力、全球化竞争的新阶段，产业链上下游优质企业将迎来业绩与估值的双重提升。葛兰称仍将积极把握板块估值与基本面改善共振带来的投资机会。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653733442","isCrawlerRequest":true}

葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向

精彩评论

葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓创新药及产业链仍是布局主要方向